Massimo Malara

Massimo Malara

Auto-generated profile, based on publicly available information

Massimo Malara


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MFMichelatonio De Fano
Michelatonio De Fano
DBDesirée Bartolini
Desirée Bartolini
CTCristina Tortoioli
Cristina Tortoioli
CVCristiana Vermigli
Cristiana Vermigli
MMMassimo Malara
Massimo Malara
GMGiuseppe Murdolo
Giuseppe Murdolo
Adipose tissue (AT) is a remarkably plastic and active organ with functional pleiotropism and high remodeling capacity. Although the expansion of fat mass, by definition, represents the hallmark of obesity, the dysregulation of the adipose organ emerges as the forefront of the link between adiposity and its associated metabolic and cardiovascular complications. The dysfunctional fat displays distinct biological signatures, which include enlarged fat cells, low-grade inflammation, impaired redox homeostasis, and cellular senescence. While these events are orchestrated in a cell-type, context-dependent and temporal manner, the failure of the adipose precursor cells to form new adipocytes appears to be the main instigator of the adipose dysregulation, which, ultimately, poses a deleterious milieu either by promoting ectopic lipid overspill in non-adipose targets (i.e., lipotoxicity) or by inducing an altered secretion of different adipose-derived hormones (i.e., adipokines and lipokines). This “adipocentric view” extends the previous “expandability hypothesis”, which implies a reduced plasticity of the adipose organ at the nexus between unhealthy fat expansion and the development of obesity-associated comorbidities. In this review, we will briefly summarize the potential mechanisms by which adaptive changes to variations of energy balance may impair adipose plasticity and promote fat organ dysfunction. We will also highlight the conundrum with the perturbation of the adipose microenvironment and the development of cardio-metabolic complications by focusing on adipose lipoxidation, inflammation and cellular senescence as a novel triad orchestrating the conspiracy to adipose dysfunction. Finally, we discuss the scientific rationale for proposing adipose organ plasticity as a target to curb/prevent adiposity-linked cardio-metabolic complications.

Verified
Journal Article
Open access
PDF file
MFMichelantonio De Fano
Michelantonio De Fano
MMMassimo Malara
Massimo Malara
CVCristiana Vermigli
Cristiana Vermigli
GMGiuseppe Murdolo
Giuseppe Murdolo
Adipose tissue (AT) represents a plastic organ that can undergo significant remodeling in response to metabolic demands. With its numerous checkpoints, the incretin system seems to play a significant role in controlling glucose homeostasis and energy balance. The importance of the incretin hormones, namely the glucagon-like peptide-1 (GLP-1) and the glucose-dependent insulinotropic peptide (GIP), in controlling the function of adipose cells has been brought to light by recent studies. Notably, a “paradigm shift” in reevaluating the role of the incretin system in AT as a potential target to treat obesity-linked metabolic disorders resulted from the demonstration that a disruption of the GIP and GLP-1 signaling axis in fat is associated with adiposity-induced insulin-resistance (IR) and/or type 2 diabetes mellitus (T2D). We will briefly discuss the (patho)physiological functions of GLP-1 and GIP signaling in AT in this review, emphasizing their potential impacts on lipid storage, adipogenesis, glucose metabolism and inflammation. We will also address the conundrum with the perturbation of the incretin axis in white or brown fat tissue and the emergence of metabolic disorders. In order to reduce or avoid adiposity-related metabolic complications, we will finally go over a potential scientific rationale for suggesting AT as a novel target for GLP-1 and GIP receptor agonists and co-agonists.

15 July 2025 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Open access
MFMichelantonio De Fano
Michelantonio De Fano
MMMassimo Malara
Massimo Malara
SRStefania Rucco
Stefania Rucco
MMMarcello Manco
Marcello Manco
CFCarmine Fanelli
Carmine Fanelli
FPFrancesca Porcellati
Francesca Porcellati
In the years immediately after its discovery, glucagon was considered only as an "antidote" for the treatment of insulin-induced hypoglycemia. The advent of specific radioimmunoassay (RIA) techniques has enabled a better understanding of glucagon's role, revealing its close connection with the pathogenesis of diabetes mellitus. This review briefly summarizes the studies regarding the pathophysiology of glucagon and its different therapeutic implications in metabolic disorders. A comprehensive literature search was conducted utilizing PubMed and Scopus, employing the keywords "glucagon", "insulin", "glucose counterregulation", and "diabetes mellitus". This search was restricted to studies published within the past fifteen years, without imposing limitations on study types. However, we mention certain historical aspects of the discovery of glucagon. In type 1 diabetes mellitus, research has concentrated on glucagon's role as a direct counterregulatory hormone to insulin, and on delineating the condition of "glucagon excess" in absolute insulin deficiency, considered a critical factor in the onset of diabetic ketoacidosis (DKA). Conversely, in type 2 diabetes mellitus, research has transitioned from glucagon antagonism to the "paradoxical" activity of glucagon agonism, given its potential positive effects on energy consumption. This has facilitated the development of incretin-based molecules with multi-receptor action, demonstrating significant clinical efficacy in glycemic control, weight loss, and hepatic fat diminution. This review highlights the fundamental role of glucagon in the pathogenesis of diabetes mellitus and its significant therapeutic implications, based on recent research findings.

4 April 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
MFMichelantonio De Fano
Michelantonio De Fano
DBDesirée Bartolini
Desirée Bartolini
CTCristina Tortoioli
Cristina Tortoioli
CVCristiana Vermigli
Cristiana Vermigli
MMMassimo Malara
Massimo Malara
GMGiuseppe Murdolo
Giuseppe Murdolo
Adipose tissue (AT) is a remarkably plastic and active organ with functional pleiot-ropism and high remodeling capacity. Although the expansion of fat mass, by defini-tion, represents the hallmark of obesity, the dysregulation of the adipose organ emerges as the forefront of the link between adiposity and its associated metabolic and cardio-vascular complications. The dysfunctional fat displays distinct biological signatures, which include enlarged fat cells (i.e., adipocyte hypertrophy), low-grade inflammation, impaired redox homeostasis, and cellular senescence. While these events are orches-trated in a cell-type, context-dependent and temporal manner, the failure of the adipose precursor cells to form new mature adipocytes appears the main instigator of the adi-pose dysregulation, which, ultimately, poses a deleterious milieu either by promoting ectopic lipid overspill in non-adipose targets (i.e., lipotoxicity) or by inducing an al-tered secretion of different adipose-derived hormones (i.e., adipokines and lipokines). This novel paradigm (“expandability hypothesis”) challenges and extends previous “adipocentric view”, which implies a reduced plasticity of the adipose organ at the nexus between “unhealthy” fat expansion and the development of obesity-associated comorbidities. In this review, we will briefly summarize the potential mechanisms by which adaptive changes to variations of energy balance may impair adipose plasticity and promote fat organ dysfunction. We will also highlight the conundrum with the perturbation of the adipose microenvironment and the development of cardio-metabolic complications by focusing on adipose lipoxidation and cellular senescence. Finally, we discuss the sci-entific rationale for proposing adipose organ plasticity as a target to curb/prevent adi-posity-linked cardio-metabolic complications.